I would like to see MERCK pull back to $81-82 range. With news coming out of FDA approval of their COVID pill it will be a quick spike to the 85-95 range and then a pullback. Approval should happen the first or second week of December. Looking at options calls for $83 if stock pulls back to $81-82.
Today we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency. Let’s analyse the chart with the Merck stocks and their upside potential. When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend....
Hello, in my series "If you had listened to me" Or "If you had followed me" you would see that from July 19th 2021 the price action for Bitcoin was just unreal. You literally could have doubled your money. So now we look at the cryptocurrency called ICP and the amazing price action. Internet Computer (ICP) is a utility token that allows users to participate...
International pharmaceutical giant Merck & Co announced the successful end of its clinical trial of the world’s first oral COVID-19 antiviral drug molnupiravir in the simple form of a pill. The company has claimed that molnupiravir effectively decreases the risk of hospitalization and death of sick individuals who have just contracted the virus or have advanced...
If stock sustain above 77 for next three trading can go long and seems to be breakout from WEEKLY TIME CORRECTION ....And long term Investor can buy this Stock for target 190 in next 2 years....with Stoploss of 70
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic...
When I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in...
I Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in...
ONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated. Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice. Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of...
MERCK (MRK), D1: Support line + Side of Bollinger bands + Hidden divergence + 2 Hammers
MERCK bullish pattern and trend. May take some days, so possible pullback and bounce on the lower support (green line). Could also channeling sideways, who knows. Difficult to lose with a warp speed candidate anyway. BUY ON FRIDAY! PT:87 at least Stop if breaks green line. Covid/Trump play. $JNJ $MRK $ABT
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure...
Hello every one Merck's stock is moving in a short-term sideways direction. With a high volumes. Between levels 73.4 and 84.7 Therefore it is advised to trade between the two levels. Good luck.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The...
JUST FINISHED TRADE, GOOD TRADE...!!!
At 8:30 AM NEWS This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer. The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much. Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news. At...